Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GluBio Therapeutics

Request full access

Engages in molecular glue-targeted protein degradation drug discovery

ChinaFounded 2021Biotech & Life Sciences

About GluBio Therapeutics

GluBio Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines through targeted protein degradation (TPD). The company operates in the biotechnology sector, primarily serving patients with unmet medical needs across various therapeutic areas. GluBio's proprietary TPD discovery platform and advanced screening capabilities enable the creation of highly selective small molecule degraders. Headquartered in San Diego, CA, with research operations in the United States and China, GluBio leverages its seasoned team of drug developers to advance its diverse pipeline. The business model revolves around the research and development of novel therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships, and potential licensing agreements.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
73.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Medical Research, Drug Development, Research and Development, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Feb 2026 $30M $120M Sanofi ↗
SERIES AOther financing Aug 2022 $22M $88M Lilly Asia Ventures · Kaitai Capital · Qiming Venture Partners ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

GluBio Therapeutics website traffic

Latest recorded traffic for GluBio Therapeutics is 1.1K monthly website visits, up 189.5% over the last three months. GluBio Therapeutics's team grew 9.1% over the past year.

Latest monthly visits1.1K 3-month web change+189.5% 1-year team growth+9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

GluBio Therapeutics in its local ecosystem

Live from Dealroom

The GluBio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See GluBio Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.